Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience-Reference-Cited by-同舟云学术

Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience

Published:2020-12-25 Issue:6 Volume:62 Page:1396-1404
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Maouche Nadjoua¹,Kishore Bhuvan²,Jenner Matthew W.³,Boyd Kevin⁴,Bhatti Zara²,Bird Sarah Anne⁴,Chander Gurvin²,Robinson Rebecca²,Vallance Grant D.¹,Offer Mark⁵,Kothari Jaimal¹,Peniket Andy¹,Aitchison Robin⁶,Dungarwalla Moez⁷,Collings Freya⁸,Bygrave Ceri⁹,Ramasamy Karthik¹

Affiliation:

1. Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

2. Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

3. Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

4. Department of Haemato-Oncology, The Royal Marsden Hospital, Sutton, UK

5. Department of Haematology, Frimley Health NHS Foundation Trust, Frimley, UK

6. Department of Haematology, Buckinghamshire Healthcare NHS Trust, Bucks, UK

7. Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK

8. Department of Haematology, Great Western Hospitals NHS Foundation Trust, Swindon, UK

9. Department of Haematology, University Hospital of Wales, Cardiff, UK

Funder

Oxford NIHR BRC Research Education and Training Group

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1864355

Reference38 articles.

1. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

2. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

3. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

4. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

5. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study;European Journal of Haematology;2024-04-23

2. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey;Journal of Chemotherapy;2023-05-21

3. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma;International Journal of Hematology;2022-11-11

4. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma;Frontiers in Oncology;2021-11-10